NIH Warns Data On Effectiveness Of Convalescent Plasma In Treating COVID-19 Is Weak
The National Institutes of Health has asked the Food and Drug Administration to delay allowing the use of convalescent plasma to treat COVID-19 because the proof of its effectiveness is weak.
Read more on NPR
The National Institutes of Health has asked the Food and Drug Administration to delay allowing the use of convalescent plasma to treat COVID-19 because the proof of its effectiveness is weak.
Read more on NPR
This is dummy text. It is not meant to be read. Accordingly, it is difficult to figure out when to end it. But then, this is dummy text. It is not meant to be read. Period.
ConversionConversion EmoticonEmoticon